Michele Tagliati MD
Movement Disorder
Professor & Vice Chair, Department of Neurology and Director, Movement Disorders at Cedars-Sinai Medical Center
Join to View Full Profile
127 S San Vicente BlvdAHSP 6600Los Angeles, CA 90048
Phone+1 310-248-6938
Fax+1 310-917-0601
Dr. Tagliati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michele Tagliati is a neurologist based in Los Angeles, CA, specializing in movement disorders. He completed his medical education at Sapienza University of Rome and furthered his training with a neurology residency and transitional year internship at the Icahn School of Medicine at Mount Sinai. Dr. Tagliati is experienced in general neurology, deep brain stimulation, movement disorders, dystonia, and essential tremor. He has authored multiple research publications, notably in the areas of Parkinson's disease and neurodegenerative disorders, and has conducted clinical trials related to Parkinson’s disease. He has been recognized with several honors, including the CMS Meaningful Use Stage 1 Certification and titles such as Most Compassionate Doctor and Super Doctor.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1996 - 1999- Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1995 - 1996
Sapienza University of RomeClass of 1986
Certifications & Licensure
CA State Medical License 2010 - 2026
NY State Medical License 1998 - 2012
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Safety and Efficacy of Liraglutide in Parkinson's Disease Start of enrollment: 2017 Apr 03
- Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) Start of enrollment: 2019 Apr 04
- Use of CereGate Therapy for Freezing of Gait in PD Start of enrollment: 2022 Apr 18
Roles: Contact
Publications & Presentations
PubMed
- 4 citationsFive-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease.Philip A Starr, Rajat S Shivacharan, Edward Goldberg, Alexander I Tröster, Paul A House
JAMA Neurology. 2025-11-01 - 1 citationsAdrenergic blockers, statins, and non-steroidal anti-inflammatory drugs are associated with later age at onset in Parkinson's disease.Camille Malatt, Helia Maghzi, Elliot Hogg, Echo Tan, Ishani Khatiwala
Journal of Neurology. 2025-03-06 - 58 citationsRelevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.Ana Westenberger, Volha Skrahina, Tatiana Usnich, Christian Beetz, Eva-Juliane Vollstedt
Brain. 2024-08-01
Press Mentions
Early Neurodegeneration May Be Detectable Through Skin in REM Sleep Behavior DisorderJune 10th, 2025- Test Detects P-SYN in Skin Biopsies of Patients with iRBDJune 6th, 2025
- Common Medications Tied to Older Age at Onset of Parkinson’s DiseaseApril 25th, 2025
Professional Memberships
- Fellow
- Movement Disorders SocietyMember
- Member
Other Languages
- Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
